Street Calls of the Week
PARIS/MANCHESTER - Lab 21 Healthcare Ltd, a non-trading subsidiary of molecular diagnostics company Novacyt S.A. (EURONEXT GROWTH:ALNOV; AIM:NCYT), has been ordered to pay a £52,000 fine following health and safety violations, the company announced Friday.
The sentencing, which took place on Thursday, relates to charges concerning the use of biological agents at Lab 21’s site in Axminster, Devon, between June 2018 and April 2019. The subsidiary had previously pleaded guilty to the charges at Exeter Magistrates Court on March 18.
The court granted full recognition for an early guilty plea in determining the fine amount. Novacyt stated in its press release that the fine will be paid from existing cash resources and "does not materially affect the Group financial position."
The Health and Safety Executive (HSE) prosecution was first announced on January 21, and according to the company, this sentencing concludes the process with "no further liability or legal action expected in relation to this case."
Novacyt is an international molecular diagnostics company with operations across multiple sectors including human health, animal health, and environmental testing. The company maintains headquarters in Le Vésinet, France, with additional offices in the UK, Singapore, the US, and Canada.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.